The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Cabozantinib as a Second-Line Treatment Option in Hepatocellular Carcinoma
Expert Rev Clin Pharmacol. 2020 May 22;1-7. doi: 10.1080/17512433.2020.1767591.Online ahead of print.
Alberto D'Angelo1, Navid Sobhani2, Stefan Bagby1, Andrea Casadei-Gardini3, Giandomenico Roviello4
Author information
1Department of Biology and Biochemistry, University of Bath, Bath, UK.
2Department of Medicine, Baylor College, Houston, TX, USA.
3Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
4Department of Health Sciences, University of Florence, Florence, Italy.
Abstract
Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor tyrosine kinases approved for renal cell carcinoma that could be useful also for the treatment of HCC.Areas covered: This review describes the chemical structure, the pharmacologic properties and current knowledge of the efficacy of cabozantinib in the treatment of HCC based on data available from first phase and later phase clinical trials. The ongoing studies testing cabozantinib, either alone or in combination with other drugs, are also described.Expert opinion: Despite the recent achievements in the use of cabozantinib for patients diagnosed with hepatocellular carcinoma, data are still needed to allow clinicians to make better decisions on how to treat specific patient subgroups.